FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:TADA2A-MED24

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: TADA2A-MED24
FusionPDB ID: 88692
FusionGDB2.0 ID: 88692
HgeneTgene
Gene symbol

TADA2A

MED24

Gene ID

6871

9862

Gene nametranscriptional adaptor 2Amediator complex subunit 24
SynonymsADA2|ADA2A|KL04P|TADA2L|hADA2ARC100|CRSP100|CRSP4|DRIP100|MED5|THRAP4|TRAP100
Cytomap

17q12

17q21.1

Type of geneprotein-codingprotein-coding
Descriptiontranscriptional adapter 2-alphaADA2-like proteintranscriptional adaptor 2 alphamediator of RNA polymerase II transcription subunit 24CRSP complex subunit 4activator-recruited cofactor 100 kDa componentcofactor required for Sp1 transcriptional activation subunit 4cofactor required for Sp1 transcriptional activation, subunit 4, 10
Modification date2020031320200313
UniProtAcc.

O75448

Main function of 5'-partner protein: FUNCTION: Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. {ECO:0000269|PubMed:12218053, ECO:0000269|PubMed:16595664}.
Ensembl transtripts involved in fusion geneENST idsENST00000591992, ENST00000225396, 
ENST00000394395, ENST00000417170, 
ENST00000586023, 		ENST00000394126, 
ENST00000479829, ENST00000356271, 
ENST00000394127, ENST00000394128, 
ENST00000501516, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score17 X 18 X 7=214216 X 15 X 7=1680
# samples 1823
** MAII scorelog2(18/2142*10)=-3.57288966842058
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(23/1680*10)=-2.86875546672175
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: TADA2A [Title/Abstract] AND MED24 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: TADA2A [Title/Abstract] AND MED24 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)TADA2A(35818689)-MED24(38192407), # samples:3
Anticipated loss of major functional domain due to fusion event.TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF.
TADA2A-MED24 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
TADA2A-MED24 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
TADA2A-MED24 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneTADA2A

GO:0043966

histone H3 acetylation

9674425

TgeneMED24

GO:0006367

transcription initiation from RNA polymerase II promoter

12218053

TgeneMED24

GO:0045893

positive regulation of transcription, DNA-templated

10198638



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:35818689/chr17:38192407)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across TADA2A (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across MED24 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000394395TADA2Achr1735802753+ENST00000394126MED24chr1738192407-389370417334601095
ENST00000586023TADA2Achr1735802753+ENST00000394126MED24chr1738192407-382863910833951095
ENST00000225396TADA2Achr1735802753+ENST00000394126MED24chr1738192407-409090137036571095
ENST00000417170TADA2Achr1735802753+ENST00000394126MED24chr1738192407-408990036936561095

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000394395ENST00000394126TADA2Achr1735802753+MED24chr1738192407-0.006230420.9937696
ENST00000586023ENST00000394126TADA2Achr1735802753+MED24chr1738192407-0.0062934560.9937065
ENST00000225396ENST00000394126TADA2Achr1735802753+MED24chr1738192407-0.0078649740.99213505
ENST00000417170ENST00000394126TADA2Achr1735802753+MED24chr1738192407-0.007857620.9921423

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for TADA2A-MED24

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
TADA2Achr1735802753MED24chr1738192407639177MAGYMPARADFIEMVSYSSVLTAISK
TADA2Achr1735802753MED24chr1738192407704177MAGYMPARADFIEMVSYSSVLTAISK
TADA2Achr1735802753MED24chr1738192407900177MAGYMPARADFIEMVSYSSVLTAISK
TADA2Achr1735802753MED24chr1738192407901177MAGYMPARADFIEMVSYSSVLTAISK

Top

Potential FusionNeoAntigen Information of TADA2A-MED24 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TADA2A-MED24_35802753_38192407.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:04ARADFIEMV0.99950.7772615
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:02ARADFIEMV0.99950.5204615
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:05ARADFIEMV0.99940.7723615
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:07ARADFIEMV0.99940.6178615
TADA2A-MED24chr1735802753chr1738192407901HLA-B39:06ARADFIEMV0.99890.9046615
TADA2A-MED24chr1735802753chr1738192407901HLA-B39:24ARADFIEMV0.99860.5999615
TADA2A-MED24chr1735802753chr1738192407901HLA-B38:02ARADFIEMV0.99660.9469615
TADA2A-MED24chr1735802753chr1738192407901HLA-B41:01IEMVSYSSV0.76330.98651120
TADA2A-MED24chr1735802753chr1738192407901HLA-B47:01ADFIEMVSY0.72880.5151817
TADA2A-MED24chr1735802753chr1738192407901HLA-B18:01ADFIEMVSY0.70330.8965817
TADA2A-MED24chr1735802753chr1738192407901HLA-B50:01IEMVSYSSV0.67050.6581120
TADA2A-MED24chr1735802753chr1738192407901HLA-B52:01IEMVSYSSV0.27840.82451120
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:01MPARADFIEM0.99650.9634414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:08MPARADFIEM0.9910.9284414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:05MPARADFIEM0.99070.8521414
TADA2A-MED24chr1735802753chr1738192407901HLA-B53:01MPARADFIEM0.9830.5877414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:03MPARADFIEM0.97760.9438414
TADA2A-MED24chr1735802753chr1738192407901HLA-B15:17RADFIEMVSY0.96090.9196717
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:04MPARADFIEM0.92820.9798414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:02MPARADFIEM0.92820.9798414
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:04ARADFIEMVSY0.99990.7306617
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:05ARADFIEMVSY0.99990.7759617
TADA2A-MED24chr1735802753chr1738192407901HLA-B15:18ARADFIEMVSY0.98090.7836617
TADA2A-MED24chr1735802753chr1738192407901HLA-C05:09RADFIEMV10.9595715
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:05ARADFIEM0.99990.9645614
TADA2A-MED24chr1735802753chr1738192407901HLA-C08:15RADFIEMV0.99990.968715
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:27ARADFIEM0.99980.9575614
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:95ARADFIEM0.99980.6864614
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:67ARADFIEM0.99940.968614
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:80ARADFIEM0.99940.968614
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:46ARADFIEM0.9990.9174614
TADA2A-MED24chr1735802753chr1738192407901HLA-C12:16ARADFIEM0.97230.9723614
TADA2A-MED24chr1735802753chr1738192407901HLA-B40:06IEMVSYSSV0.99960.621120
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:14ARADFIEMV0.99950.7556615
TADA2A-MED24chr1735802753chr1738192407901HLA-B39:12ARADFIEMV0.99750.9094615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:05ARADFIEMV0.99570.9687615
TADA2A-MED24chr1735802753chr1738192407901HLA-B73:01ARADFIEMV0.99340.8189615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:27ARADFIEMV0.9870.9645615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:95ARADFIEMV0.98390.7242615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:29ARADFIEMV0.98250.9265615
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:03ARADFIEMV0.97490.7948615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:13ARADFIEMV0.96550.9588615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:46ARADFIEMV0.91030.9458615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:80ARADFIEMV0.8860.9757615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:67ARADFIEMV0.8860.9757615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:19ARADFIEMV0.88410.8507615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:10ARADFIEMV0.87160.984615
TADA2A-MED24chr1735802753chr1738192407901HLA-B51:07IEMVSYSSV0.1290.75581120
TADA2A-MED24chr1735802753chr1738192407901HLA-C12:16ARADFIEMV0.00750.9777615
TADA2A-MED24chr1735802753chr1738192407901HLA-B07:12MPARADFIEM0.99310.5441414
TADA2A-MED24chr1735802753chr1738192407901HLA-B42:02MPARADFIEM0.93390.6981414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:12MPARADFIEM0.92820.9798414
TADA2A-MED24chr1735802753chr1738192407901HLA-B42:01MPARADFIEM0.92780.6877414
TADA2A-MED24chr1735802753chr1738192407901HLA-B15:07RADFIEMVSY0.92520.8291717
TADA2A-MED24chr1735802753chr1738192407901HLA-B39:10MPARADFIEM0.8970.9046414
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:14ARADFIEMVSY0.99970.724617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:27ARADFIEMVSY0.99970.9517617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:95ARADFIEMVSY0.99950.6705617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:05ARADFIEMVSY0.99950.9621617
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:03ARADFIEMVSY0.99910.7991617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:19ARADFIEMVSY0.99870.7528617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:80ARADFIEMVSY0.99810.9558617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:67ARADFIEMVSY0.99810.9558617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:46ARADFIEMVSY0.99720.9162617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:10ARADFIEMVSY0.99580.9712617
TADA2A-MED24chr1735802753chr1738192407901HLA-C01:30YMPARADFIEM0.98820.9614314
TADA2A-MED24chr1735802753chr1738192407901HLA-C12:16ARADFIEMVSY0.94050.9586617
TADA2A-MED24chr1735802753chr1738192407901HLA-C05:01RADFIEMV10.9595715
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:01ARADFIEM0.99990.6724614
TADA2A-MED24chr1735802753chr1738192407901HLA-C08:02RADFIEMV0.99990.968715
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:22ARADFIEM0.99960.7259614
TADA2A-MED24chr1735802753chr1738192407901HLA-C06:08ARADFIEM0.99960.9958614
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:17ARADFIEM0.99960.9725614
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:02ARADFIEM0.99940.968614
TADA2A-MED24chr1735802753chr1738192407901HLA-B18:04DFIEMVSY0.97760.8635917
TADA2A-MED24chr1735802753chr1738192407901HLA-B18:07DFIEMVSY0.96910.814917
TADA2A-MED24chr1735802753chr1738192407901HLA-C06:17ARADFIEM0.96310.9954614
TADA2A-MED24chr1735802753chr1738192407901HLA-C06:02ARADFIEM0.96310.9954614
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:09ARADFIEMV0.99960.7541615
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:06ARADFIEMV0.99950.8116615
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:10ARADFIEMV0.99950.8812615
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:08ARADFIEMV0.99940.6782615
TADA2A-MED24chr1735802753chr1738192407901HLA-B39:31ARADFIEMV0.99790.9072615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:01ARADFIEMV0.98340.7256615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:17ARADFIEMV0.9780.9767615
TADA2A-MED24chr1735802753chr1738192407901HLA-C06:08ARADFIEMV0.94790.9961615
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:02ARADFIEMV0.8860.9757615
TADA2A-MED24chr1735802753chr1738192407901HLA-B18:04ADFIEMVSY0.8670.9073817
TADA2A-MED24chr1735802753chr1738192407901HLA-B18:11ADFIEMVSY0.83740.8667817
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:04ARADFIEMV0.79920.9481615
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:28ADFIEMVSY0.77880.8942817
TADA2A-MED24chr1735802753chr1738192407901HLA-B41:03IEMVSYSSV0.74750.76121120
TADA2A-MED24chr1735802753chr1738192407901HLA-B18:08ADFIEMVSY0.72120.7002817
TADA2A-MED24chr1735802753chr1738192407901HLA-B18:05ADFIEMVSY0.70330.8965817
TADA2A-MED24chr1735802753chr1738192407901HLA-C06:06ARADFIEMV0.69930.9932615
TADA2A-MED24chr1735802753chr1738192407901HLA-B18:06ADFIEMVSY0.69050.8953817
TADA2A-MED24chr1735802753chr1738192407901HLA-B50:04IEMVSYSSV0.67050.6581120
TADA2A-MED24chr1735802753chr1738192407901HLA-B50:05IEMVSYSSV0.67050.6581120
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:22ARADFIEMV0.59980.7596615
TADA2A-MED24chr1735802753chr1738192407901HLA-C06:02ARADFIEMV0.040.9965615
TADA2A-MED24chr1735802753chr1738192407901HLA-C06:17ARADFIEMV0.040.9965615
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:23MPARADFIEM0.99650.9648414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:77MPARADFIEM0.99650.9634414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:30MPARADFIEM0.9910.9398414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:17MPARADFIEM0.9910.9398414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:11MPARADFIEM0.98230.9717414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:13MPARADFIEM0.97610.9473414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:24MPARADFIEM0.96660.9331414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:09MPARADFIEM0.92820.9798414
TADA2A-MED24chr1735802753chr1738192407901HLA-B15:35RADFIEMVSY0.91020.9412717
TADA2A-MED24chr1735802753chr1738192407901HLA-B67:01MPARADFIEM0.90840.8231414
TADA2A-MED24chr1735802753chr1738192407901HLA-B15:08MPARADFIEM0.85750.954414
TADA2A-MED24chr1735802753chr1738192407901HLA-B15:11MPARADFIEM0.85710.9554414
TADA2A-MED24chr1735802753chr1738192407901HLA-B35:43MPARADFIEM0.85310.9567414
TADA2A-MED24chr1735802753chr1738192407901HLA-B56:05MPARADFIEM0.74410.5275414
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:08ARADFIEMVSY0.99990.6693617
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:10ARADFIEMVSY0.99990.8381617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:01ARADFIEMVSY0.99960.651617
TADA2A-MED24chr1735802753chr1738192407901HLA-B27:09ARADFIEMVSY0.99930.7473617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:22ARADFIEMVSY0.99810.7424617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:02ARADFIEMVSY0.99810.9558617
TADA2A-MED24chr1735802753chr1738192407901HLA-C07:17ARADFIEMVSY0.99680.9597617
TADA2A-MED24chr1735802753chr1738192407901HLA-C01:02YMPARADFIEM0.98940.9318314
TADA2A-MED24chr1735802753chr1738192407901HLA-B15:54ARADFIEMVSY0.94260.8803617
TADA2A-MED24chr1735802753chr1738192407901HLA-B15:68ARADFIEMVSY0.93160.7368617
TADA2A-MED24chr1735802753chr1738192407901HLA-B51:09MPARADFIEMV0.87690.5691415

Top

Potential FusionNeoAntigen Information of TADA2A-MED24 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TADA2A-MED24_35802753_38192407.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TADA2A-MED24chr1735802753chr1738192407901DRB1-0901MAGYMPARADFIEMV015
TADA2A-MED24chr1735802753chr1738192407901DRB1-0904MAGYMPARADFIEMV015
TADA2A-MED24chr1735802753chr1738192407901DRB1-0905MAGYMPARADFIEMV015
TADA2A-MED24chr1735802753chr1738192407901DRB1-0907MAGYMPARADFIEMV015
TADA2A-MED24chr1735802753chr1738192407901DRB1-0909MAGYMPARADFIEMV015

Top

Fusion breakpoint peptide structures of TADA2A-MED24

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
537ARADFIEMVSYSSVTADA2AMED24chr1735802753chr1738192407901

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TADA2A-MED24

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN537ARADFIEMVSYSSV-7.9962-8.1096
HLA-B14:023BVN537ARADFIEMVSYSSV-5.70842-6.74372
HLA-B52:013W39537ARADFIEMVSYSSV-6.83737-6.95077
HLA-B52:013W39537ARADFIEMVSYSSV-4.4836-5.5189
HLA-A11:014UQ2537ARADFIEMVSYSSV-10.0067-10.1201
HLA-A11:014UQ2537ARADFIEMVSYSSV-9.03915-10.0745
HLA-A24:025HGA537ARADFIEMVSYSSV-6.56204-6.67544
HLA-A24:025HGA537ARADFIEMVSYSSV-5.42271-6.45801
HLA-B44:053DX8537ARADFIEMVSYSSV-7.85648-8.89178
HLA-B44:053DX8537ARADFIEMVSYSSV-5.3978-5.5112
HLA-A02:016TDR537ARADFIEMVSYSSV-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of TADA2A-MED24

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
TADA2A-MED24chr1735802753chr17381924071120IEMVSYSSVATTGAGATGGTGTCCTACTCTTCTGTC
TADA2A-MED24chr1735802753chr1738192407314YMPARADFIEMTACATGCCAGCTCGAGCAGATTTCATTGAGATG
TADA2A-MED24chr1735802753chr1738192407414MPARADFIEMATGCCAGCTCGAGCAGATTTCATTGAGATG
TADA2A-MED24chr1735802753chr1738192407415MPARADFIEMVATGCCAGCTCGAGCAGATTTCATTGAGATGGTG
TADA2A-MED24chr1735802753chr1738192407614ARADFIEMGCTCGAGCAGATTTCATTGAGATG
TADA2A-MED24chr1735802753chr1738192407615ARADFIEMVGCTCGAGCAGATTTCATTGAGATGGTG
TADA2A-MED24chr1735802753chr1738192407617ARADFIEMVSYGCTCGAGCAGATTTCATTGAGATGGTGTCCTAC
TADA2A-MED24chr1735802753chr1738192407715RADFIEMVCGAGCAGATTTCATTGAGATGGTG
TADA2A-MED24chr1735802753chr1738192407717RADFIEMVSYCGAGCAGATTTCATTGAGATGGTGTCCTAC
TADA2A-MED24chr1735802753chr1738192407817ADFIEMVSYGCAGATTTCATTGAGATGGTGTCCTAC
TADA2A-MED24chr1735802753chr1738192407917DFIEMVSYGATTTCATTGAGATGGTGTCCTAC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
TADA2A-MED24chr1735802753chr1738192407015MAGYMPARADFIEMVATGGCCGGGTACATGCCAGCTCGAGCAGATTTCATTGAGATGGTG

Top

Information of the samples that have these potential fusion neoantigens of TADA2A-MED24

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCATADA2A-MED24chr1735802753ENST00000225396chr1738192407ENST00000394126TCGA-AR-A0TQ

Top

Potential target of CAR-T therapy development for TADA2A-MED24

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to TADA2A-MED24

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to TADA2A-MED24

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource